What is the mechanism of action (MOA) of Nicorandil?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 20, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Mechanism of Action of Nicorandil

Nicorandil has a dual mechanism of action as both a potassium channel activator and a nitrate donor, making it unique among antianginal medications.

Primary Mechanisms

1. Potassium Channel Activation

  • Activates ATP-sensitive potassium (KATP) channels in vascular smooth muscle 1
  • This activation leads to:
    • Arterial vasodilation
    • Reduction in afterload
    • Decreased myocardial oxygen demand
    • Potential cardioprotective effects through ischemic preconditioning 2

2. Nitrate-like Effects

  • Contains a nitrate moiety in its chemical structure 3
  • Produces venodilation through nitric oxide (NO) donation 4
  • Results in:
    • Decreased preload
    • Reduced left ventricular end-diastolic pressure
    • Decreased myocardial wall tension

Hemodynamic Effects

  • Balanced coronary and peripheral vasodilation 2
  • Reduction in both preload and afterload 5
  • Decreased total peripheral resistance (approximately 19%) 5
  • Reduced systolic (34%) and diastolic (21%) blood pressure 5
  • Does not impair myocardial contractility or atrioventricular conduction 5

Cardioprotective Properties

  • Involvement in myocardial preconditioning 6
  • Potential protection against ischemia-reperfusion injury 2
  • Reduction in ST-segment elevation during ischemia in patients undergoing coronary angioplasty 2
  • Improvement in regional left ventricular wall motion after ischemic damage 2
  • Strong spasmolytic activity against coronary vasospasm 5

Mechanism Predominance in Different Conditions

The relative contribution of each mechanism varies depending on:

  • Dose of nicorandil administered
  • Target tissue/organ
  • Underlying pathophysiology 4

For example:

  • KATP channel opening predominates in models of myocardial and pulmonary fibrosis
  • NO donation is the primary mechanism in hepatic fibrosis and inflammatory bowel diseases 4

Clinical Implications

  • Effective antianginal agent at doses of 10-40 mg 5
  • Sustained efficacy with no evidence of tolerance development 5
  • Equivalent efficacy to beta-blockers and calcium channel blockers in comparative trials 2
  • May have additional benefits in patients with vasospastic angina 3

Common Side Effects

  • Headache (most common, occurs in approximately one-third of patients) 3
  • Usually mild to moderate in intensity
  • Tends to diminish with continued treatment
  • Can be minimized by starting at a lower dose (5 mg twice daily) 3
  • Other potential side effects: facial flushing, hypotension, and rarely, mouth ulcers 2

Nicorandil's unique dual mechanism provides effective angina management while potentially offering additional cardioprotective benefits not seen with other antianginal medications.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.